A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms China Extension Study; LEAP-010; MK-7902-010
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 18 Apr 2025 Status changed from active, no longer recruiting to completed.
- 25 Mar 2025 Planned End Date changed from 1 Mar 2025 to 31 Mar 2025.
- 16 Apr 2024 Planned End Date changed from 29 Jul 2026 to 1 Mar 2025.